251 related articles for article (PubMed ID: 20601445)
21. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
[TBL] [Abstract][Full Text] [Related]
22. Critical requirement for Stat5 in a mouse model of polycythemia vera.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
[TBL] [Abstract][Full Text] [Related]
23. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
Gaikwad A; Prchal JT
Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
[TBL] [Abstract][Full Text] [Related]
24. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
[TBL] [Abstract][Full Text] [Related]
25. Application of mutant JAK2V617F for in vitro generation of red blood cells.
Lee SA; Kim JY; Choi Y; Kim Y; Kim HO
Transfusion; 2016 Apr; 56(4):837-43. PubMed ID: 26646156
[TBL] [Abstract][Full Text] [Related]
26. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
Falchi M; Varricchio L; Martelli F; Marra M; Picconi O; Tafuri A; Girelli G; Uversky VN; Migliaccio AR
Exp Hematol; 2017 Jun; 50():53-76. PubMed ID: 28232234
[TBL] [Abstract][Full Text] [Related]
27. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice.
Jin X; Zhao W; Kirabo A; Park SO; Ho WT; Sayeski PP; Zhao ZJ
J Immunol; 2014 Jul; 193(2):477-84. PubMed ID: 24920845
[TBL] [Abstract][Full Text] [Related]
28. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
[TBL] [Abstract][Full Text] [Related]
29. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
30. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Patel AB; Franzini A; Leroy E; Kim SJ; Pomicter AD; Genet L; Xiao M; Yan D; Ahmann JM; Agarwal AM; Clair P; Addada J; Lambert J; Salmon M; Gleich GJ; Cross NCP; Constantinescu SN; O'Hare T; Prchal JT; Deininger MW
Blood; 2019 Dec; 134(26):2388-2398. PubMed ID: 31697804
[TBL] [Abstract][Full Text] [Related]
31. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
32. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
33. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
34. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of microRNA in polycythemia vera.
Bruchova H; Merkerova M; Prchal JT
Haematologica; 2008 Jul; 93(7):1009-16. PubMed ID: 18508790
[TBL] [Abstract][Full Text] [Related]
36. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
[TBL] [Abstract][Full Text] [Related]
37. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
Lu M; Wang J; Li Y; Berenzon D; Wang X; Mascarenhas J; Xu M; Hoffman R
Blood; 2010 Nov; 116(20):4284-7. PubMed ID: 20625010
[TBL] [Abstract][Full Text] [Related]
38. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
[TBL] [Abstract][Full Text] [Related]
39. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
40. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.
Chen E; Beer PA; Godfrey AL; Ortmann CA; Li J; Costa-Pereira AP; Ingle CE; Dermitzakis ET; Campbell PJ; Green AR
Cancer Cell; 2010 Nov; 18(5):524-35. PubMed ID: 21074499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]